Loading
Journal of Cancer Immunology
ISSN: 2689-968X
Volume 4, Issue 1, p1-32
Articles published in this issue are Open Access and licensed under Creative Commons Attribution License (CC BY NC) where the readers can reuse, download, distribute the article in whole or part by mentioning proper credits to the authors.
Clinical, FDG-PET and Molecular Markers of Immune Checkpoint Inhibitor Response in Patients with Advanced Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) is a rare, highly aggressive, neuroendocrine cancer of the skin with an increasing incidence. MCC occurs predominantly in older adults with risk factors including high exposure to ultra-violet (UV) light and immunosuppression.
J Cancer Immunol, 2022, Volume 4, Issue 1, p1-11 | DOI: 10.33696/cancerimmunol.4.058MEK Inhibition in KRAS Mutated NSCLC: Quo vadis?
Lung cancer continues to be the leading cause of cancer deaths worldwide. Approximately 85% of lung cancers are histologically classified as non-small cell lung cancer (NSCLC) of which adenocarcinoma is the most frequent subtype.
J Cancer Immunol, 2022, Volume 4, Issue 1, p12-16 | DOI: 10.33696/cancerimmunol.4.059Cancer-Related Pain: Inside a New Dynamic Personalized Approach. A Narrative Review
Chronic cancer-related pain, according to the latest International Classification of Diseases (ICD-11), is defined as “chronic pain caused by the primary cancer itself or metastases (chronic cancer pain) or its treatment (chronic post-cancer treatment pain)”.
J Cancer Immunol, 2022, Volume 4, Issue 1, p17-21 | DOI: 10.33696/cancerimmunol.4.060Emerging Potential of Plant Virus Nanoparticles (PVNPs) in Anticancer Immunotherapies
Plant virus nanoparticles (PVNPs) are increasingly recognized and studied for use in biomedical applications. PVNPs include plant virions with self-assembled capsid protein coats (PC) that encapsulate the virus genome, and virus-like particles (VLPs), a capsid without the viral genome.
J Cancer Immunol, 2022, Volume 4, Issue 1, p22-29 | DOI: 10.33696/cancerimmunol.4.061OGR1-a Novel Modulator Target of Tumor Immunotherapy
Tumors mainly utilize glucose to promote aerobic glycolysis for their survival (Warburg effect). The highly glycolytic environment is not suitable for the survival and function of effector T cells, and leads to the decline of antitumor immunity.
J Cancer Immunol, 2022, Volume 4, Issue 1, p30-32 | DOI: 10.33696/cancerimmunol.4.062Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Prospective Evaluation of Effect of Metformin on Activation of AMP-activated Protein Kinase (AMPK) and Disease Control in a Sub-group Analysis of Patients with GI Malignancies
Observational studies have demonstrated association of metformin with reduced cancer incidence and mortality in multiple cancer types, including gastrointestinal (GI) malignancies. Anti-neoplastic effects of metformin are believed through many mechanisms including activation of AMP-activated protein kinase, which controls mammalian target of rapamycin (mTOR) growth regulatory pathway.
Development of Metal Oxide Nanoparticles as Semiconductors
The variety of methods employed during the fabrication of MONPs can alter the characteristics and control the properties of the obtained nano-oxides. The reaction mechanisms and, therefore, the functionality of nanostructured MOx depend on their composition
Impact of Cisplatin Dosing Regimens on Mammary Tumor Growth in an Animal Model
In a recent paper, we introduced a variant of the classical Simeoni tumor growth model, and illustrated its value in assessing tumor growth in a reproducible mouse model for mammary tumors. Our modification consisted of incorporating delay differential equations in the mathematical formulation of the Simeoni model, to represent the delay in drug action often observed under chemotherapeutic or immunotherapeutic regimens.
Deubiquitinase as Potential Targets for Cancer Immunotherapy
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.
The Effect of Glucocorticoids on Angiogenesis in the Treatment of Solid Tumors
Glucocorticoids (GCs) are defined by their role in maintaining glucose homeostasis and natural GCs are a class of corticosteroids secreted by the adrenal cortex. Cortisol is the most important natural GC in humans. Cellular cortisol levels are regulated by the tissue-specific metabolic enzymes 11β-hydroxysteroid dehydrogenase 1 and 2 (11β-HSD 1 and 2); 11β-HSD 1 converts inactive cortisone to active cortisol, while 11β-HSD 2 has the opposite function.
Role of the Gut Microbiome in the Modulation of Cancer Immunotherapy Response
The gut microbiome or gut flora is a vast community of microorganisms such as bacteria, viruses, protozoa, and fungi that inhabit the digestive tract of the human and other animals. In the human body, bacterial species colonize into the oral cavity, skin, vagina, and placenta, however, the largest population of microorganisms resides in the intestine. The majority of gut microbiota belong to the phyla Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.
Do Support Vector Machines Play a Role in Stratifying Patient Population Based on Cancer Biomarkers
Cancer is a worldwide public health issue that affects millions of people every year. In 2018 there were 17 million newly documented cases of cancer globally (8.8 million in men and 8.2 million in women), leading to 9.6 million deaths. Cancer is a vastly heterogeneous disease, with over 100 different types of cancer currently identified in humans; the most common types of cancer are lung, female breast, bowel and prostate, these four types account for more than 40% of all new cancer case
Prognostic Role of Human Epididymis Protein 4 (HE4) in Ovarian Cancer Treatment: Our Point of View
In the last 10 years, the marker “Human Epididymis protein 4 (HE4)” for the management of gynecological tumors has entered powerfully in the world literature. At the moment, carrying out an accurate research in the main scientific portals such as PubMed, we can find more than 2,000 works concerning Cancer antigen-125 (Ca125), but those concerning HE4 are less than 400. The assessment of the prognostic significance of Ca125 has been described in more than 1000 scientific papers, whereas in the case of HE4 such works are only about 100.
Can Filtration Technology Advance Culture of Circulating Tumor Cells towards Precision Medicine?
Expansion of Circulating Tumor Cells (CTC), the metastatic seeds of cancer in the blood stream, holds great potential in clinical application, especially towards precision medicine. Given the relatively rare nature of CTCs, their culture remains to be a significant challenge. When developing technologies for CTC culture, there are key elements that need careful consideration, including the speed of culture, compatibility with downstream analysis, and the implementation of the technology into established clinical daily routines. Herein, we briefly discuss the implications of our recent report of an ultrathin filter for the capture and culture of circulating colon cancer cells.
Influence of Clinical Risk Factors on Outcomes in Men with Stage I Non-Seminomatous Germ Cell Tumor Undergoing Robot-Assisted Retroperitoneal Lymph Node Dissection
We recently published our multi-institutional experience performing primary robot-assisted retroperitoneal lymph node dissection (RA-RPLND) for men with non-seminomatous germ cell tumor (NSGCT). We concluded that primary RA-RPLND for NSGCT can be performed safely with low complication rates, acceptable early oncologic outcomes, and lower overall theoretical chemotherapy burden. In this commentary, we explore outcomes in clinical stage I patients stratified by clinical risk factors (RF) and estimate reductions in chemotherapy burden.
Forces, Chromosomal Configurations, and Carcinogenesis: Towards Another Therapeutic Approach
Previous studies of in vitro and in vivo morphogenesis may suggest a more inclusive principle governing biological processes. In this regard, methylglyoxal (MG) in very low, non-toxic concentrations and ascorbic acid have been shown to promote in vitro morphogenesis in various types of plants. Forces of cohesion and adhesion might be involved in such development. These are conveyed through the electronic desaturation of protein by means of MG and ascorbic acid.
Botulinum Toxin: The Promising Future of Prostate Cancer Treatment
Peripheral nerves have been shown to modulate the growth and spread of tumours in the prostate, feeding both cancer cells and the stroma in the tumour environment. Several in vitro and in vivo studies have reported the effect of botulinum toxin (BT) on tumour tissue in the prostate. BT in humans has been observed to cause increased apoptosis of cancer cells, with morphological changes characterized by extensive degenerative and atrophic areas of cancer, reduced cytoplasm, and pyknotic nuclei, compared to the characteristics of cancer tissues injected with saline solution.
Primary Small Cell Neuroendocrine Carcinoma of Bladder – A Rare Diagnostic Entity
Primary small cell carcinoma of the bladder is very rare pathological entity, follows an aggressive course and carries poor prognosis. The literature carrying these articles are scarce and due to which it poses a diagnostic challenge to the radiologist and urologists. Herein, we present a case of small cell carcinoma of urinary bladder in a 75-year-old male patient initially reported as poorly differentiated urothelial carcinoma on transurethral resection of bladder tumor specimen to emphasize its rarity as well as the role of immunohistochemistry to differentiate between the two.
Salivary Protein Antigens for Breast Cancer Biomarkers
Breast Cancer is the most regularly diagnosed type of cancer in women in the world, making up on its own 25% of all cases, or nearly 2 million new cases in 2018, and 15% of all cancer related deaths, or around 626,700 deaths for that same year.
Commentary on "The Gene Master Regulators GMR Approach Provides Legitimate Targets for Personalized, Time-Sensitive Cancer Gene Therapy"
For decades, the scientific community tried hard to identify the gene biomarkers whose mutations or regulations cause (better say are associated with) specific forms of cancer. For instance, the September 17th 2019 release of the Genomic Data Commons Data Portal includes 3,142,246 mutations detected in 22,872 genes sequenced from 37,075 cases of cancers localized in 67 primary sites.
Leucocyte-Tumor Cell Hybridization Can Initiate Cancer Metastasis
According to estimates from the International Agency for Research on Cancer, by the year 2030 there will be 22 million new cancer cases and 13 million deaths per year. The main reason for death from cancer is not the initial tumor but it’s metastasis to distant parts of the body, yet this process has remained poorly understood for quite some time.
NOXA the BCL-2 Family Member behind the Scenes in Cancer Treatment
NOXA is a critical mediator of stress responses to anticancer drugs. This BH3-only protein sets the apoptotic threshold in cancer cells in response to chemotherapies by counteracting the prosurvival BCL-2 family protein MCL-1. A complex and dynamic network relying on both highly controlled gene transcription activity and protein degradation by proteasome, regulates cellular NOXA levels from low in steady state to rapidly enhanced upon stressful condition.
Gene Therapy for Sickle Cell Disease: Start of a New Era
This manuscript reviews treatment of Sickle Cell disease over time. The application of allogeneic stem cells proved the sickle cell disease could be permanently corrected and cured but limited to those with a compatible donor.
CTLA-4 and PD-L1 or PD-1 Pathways: Immune Checkpoint Inhibitors and Cancer Immunotherapy
The immune system developed certain checks and balance to control or inhibit the reactivity against normal cells of the body. Uncontrolled immune responses to the non-self entities such as bacteria, viruses, parasites, or mutated self-antigens can cause an inflammatory reaction and autoimmune diseases.
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.